INO Inovio Pharmaceuticals: Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan

Inovio Pharmaceuticals (INO) develops DNA-based therapies for cancer and viruses, aiming for stable cash flow through commercialization. The GURU.Markets platform displays the quarterly EPS change, where 42.90 defines the current value of the metric. The company's success depends on regulatory approvals, and the implementation of a direct genetic code delivery platform will accelerate the protection of humanity against new pandemics.

Inovio (INO) - Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan saka 04.07.2022 nganti 15.11.2026

Rincian analitis perusahaan Inovio Pharmaceuticals

- rega saham lan konsensus proyeksi valuasi:

Kutipan saham Inovio Pharmaceuticals, Inc.|INO - Prakiraan konsensus analis

- data kapitalisasi saham perusahaan:

Nilai pasar Inovio Pharmaceuticals, Inc.|INO - Rega Tumbas Perusahaan

- data kapitalisasi buku:

Nilai Buku saben Saham Inovio|INO - Pambiji Buku Bisnis|Rasio Nilai Pasar marang Nilai Buku inovio.com|INO - Total Aset Bisnis

- data tingkat utang lan likuiditas finansial:

- indikator bathi lan kelipatan valuasi:

INO - Bathi pungkasan|Bathi sing dikarepake Inovio Pharmaceuticals|INO - Kapitalisasi marang bathi resik|Pangali Forward P/E Inovio Pharmaceuticals|INO - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Inovio Pharma|INO - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Inovio|INO - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan inovio.com|INO - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Inovio Pharmaceuticals

- data dodolan lan asil:

INO - Pendapatan lan volume dodolan|Prakiraan volume dodolan Inovio Pharma|INO - Kapitalisasi marang pendapatan|Multiplikator Forward P/S Inovio Pharmaceuticals Inc|INO - Wutah pendapatan taun lumaku

Pambiji fundamental:Inovio Pharma - INO

The absence of commercial DNA vaccine sales for Inovio Pharmaceuticals (INO) makes pricing dependent on clinical trial outcomes. Under these conditions, quarterly EPS growth reflects the dynamics of net income per share, accounting for operational R&D expenses. This metric measures capital management efficiency and the cash burn rate. It is critical for investors to distinguish systemic progress from random fluctuations. By analyzing the quarterly EPS change, one can assess the actual resilience of the business.

Pesaing Inovio Pharmaceuticals (INO)